BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9842923)

  • 1. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major.
    Flohé SB; Bauer C; Flohé S; Moll H
    Eur J Immunol; 1998 Nov; 28(11):3800-11. PubMed ID: 9842923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
    Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
    J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
    von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
    Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
    Remer KA; Apetrei C; Schwarz T; Linden C; Moll H
    Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine epidermal Langerhans cells are potent stimulators of an antigen-specific T cell response to Leishmania major, the cause of cutaneous leishmaniasis.
    Will A; Blank C; Röllinghoff M; Moll H
    Eur J Immunol; 1992 Jun; 22(6):1341-7. PubMed ID: 1601029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8 alpha- and Langerin-negative dendritic cells, but not Langerhans cells, act as principal antigen-presenting cells in leishmaniasis.
    Ritter U; Meissner A; Scheidig C; Körner H
    Eur J Immunol; 2004 Jun; 34(6):1542-50. PubMed ID: 15162423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells.
    Moll H; Fuchs H; Blank C; Röllinghoff M
    Eur J Immunol; 1993 Jul; 23(7):1595-601. PubMed ID: 8325337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin-derived macrophages from Leishmania major-susceptible mice exhibit interleukin-12- and interferon-gamma-independent nitric oxide production and parasite killing after treatment with immunostimulatory DNA.
    von Stebut E; Belkaid Y; Nguyen B; Wilson M; Sacks DL; Udey MC
    J Invest Dermatol; 2002 Sep; 119(3):621-8. PubMed ID: 12230504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK
    East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.
    Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP
    Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
    Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
    Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the immunological memory state generated in mice susceptible to Leishmania major following exposure to low doses of L. major and resulting in resistance to a normally pathogenic challenge.
    Menon JN; Bretscher PA
    Eur J Immunol; 1996 Jan; 26(1):243-9. PubMed ID: 8566074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity.
    von Stebut E; Belkaid Y; Jakob T; Sacks DL; Udey MC
    J Exp Med; 1998 Oct; 188(8):1547-52. PubMed ID: 9782133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.